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Abstract
Background Arthritis is the leading cause of disability in
the United States. We assess the generic health-related
quality-of-life (HRQOL) among a nationally representative
sample of US adults with and without self-reported
arthritis.
Methods The NHMS, a cross-sectional survey of 3,844
adults (35–89 years) administered EuroQol-5D (EQ-5D),
Health Utilities Index Mark 2 (HUI2) and 3 (HUI3), SF-
36v2
TM, Quality of Well-being Scale self-administered
form (QWB-SA), and the Health and Activities Limitations
index (HALex) to each respondent via a telephone
interview. Weighted multiple linear regression was used to
generate age-gender-arthritis-stratiﬁed unadjusted HRQOL
means and means adjusted for sociodemographic, socio-
economic covariates and comorbidities by arthritis–age
category.
Results The estimated population prevalence of self-
reported arthritis was 31%. People with arthritis were more
likely to be woman, older, of lower socioeconomic status,
and had more self-reported comorbidities than were those
not reporting arthritis. Adults with arthritis had lower
HRQOL on six different indexes compared with adults
without arthritis, with overall differences ranging from
0.03 (QWB-SA, age-group 65–74) to 0.17 (HUI3, age-
group 35–44; all P-value\.05).
Conclusion Arthritis in adults is associated with poorer
HRQOL. We provide age-related reference values for six
generic HRQOL measures in people with arthritis.
Keywords Health-Related Quality of Life  HRQOL 
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Introduction
Arthritis affects approximately 46.4 million people in
United States (US) [1], is the leading cause of physical
disability, and has a detrimental effect on health-related
quality of life (HRQOL) [2]. Measuring and monitoring
population HRQOL can help guide public policy by iden-
tifying vulnerable populations, tracking population trends,
and assessing the impact of established policies on HRQOL
relative to established national averages [3]. HRQOL
measures summarize multiple dimensions of health into a
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the physical, mental, and social dimensions of health [4].
Disease-speciﬁc measures for arthritis such as the Arthritis
Impact Measurement Scales (AIMS) [5, 6] or the Health
Assessment Questionnaire (HAQ) [7] ask patients about
selected activities and experiences that are generally
assumed to be affected by the disease. Generic HRQOL
indexes are not targeted to a speciﬁc disease experience,
but instead attempt to summarize function and well-being
across a comprehensive set of domains that are conceptu-
alized to underpin health as experienced by an individual.
Preference-based generic indexes are scored by summa-
rizing across health domains using so-called preference
weights, systematically collected from a general population
sample of adults. These utility-based measures summarize
multiple domains and place overall wellness on a contin-
uum ranging from 0.0 (health state of dead) to 1.0 (health
state of perfect or full health) using measure-speciﬁc
community preference-weighted scoring functions. These
measures can be used to adjust survival time for quality of
life and are designed to yield quality-adjusted life years
(QALYs) that can be used in cost-effectiveness analysis.
Population-level HRQOL data have been reported for
several chronic diseases, including arthritis [2, 8–22]. Ko
and Coons reported US-based EuroQol-5D (EQ-5D) scores
for chronic conditions (including arthritis) from the US
population and reported relative HRQOL decrements
associated with various chronic conditions [22]. Anderson
and colleagues assessed decrements in Quality of Well-
Being (QWB) associated with self-reported arthritis in the
National Health Interview Survey (NHIS) data [15]. Mo
and colleagues analyzed Health utilities Index (HUI) in the
Canadian Community Health Survey (CCHS) for
2000–2001 and reported that arthritis/rheumatism has a
severe impact on HRQOL [19]. However, no study has
directly compared commonly used HRQOL measures in a
population-based survey in United States.
The present study assesses the impact of self-reported
arthritis in the US adult population using six widely used
generic indexes and provides reference HRQOL values for
these measures in people with arthritis.
Materials and methods
We utilized data from the National Health Measurement
Study (NHMS) [23]—a national cross-sectional sample of
adults in United States where EuroQol-5D (EQ-5D) [24],
Health Utilities Index Mark 2 (HUI2) [25], Health Utilities
Index Mark 3 (HUI3) [26], SF-6D (a summary index
derived from the SF-36v2
TM questionnaire) [27], Quality
of Well-being Scale self-administered form (QWB-SA)
[28], and the Health and Activities Limitations index
(HALex) [29] were all administered via a telephone
interview to each respondent.
NHMS was a random digit-dialed (RDD) telephone
interview of a sample of 3,844 adults aged 35–89 years,
designed to represent the older half of the non-institution-
alized US population in 2000 (median age was 36.4 years,
http://factﬁnder.census.gov) from the continental United
States [23]. People aged 65–89, and telephone exchanges
with high percentages of African Americans were over-
sampled. When a household with at least one resident aged
35–89 was contacted, one of the three age ranges (35–44,
45–64, 65?) was sampled using pre-speciﬁed weights
favoring older ages to determine who if anyone would be
interviewed. If there were more than one person in the
selected age range, the Troldahl-Carter-Bryant method [30]
was used to select a respondent. At most one person was
selected per household. Each respondent completed the six
HRQOL instruments. Our case deﬁnition of arthritis was
based on self-reported arthritis [1, 31]: ‘‘Have you ever
been told (by a doctor or other health professional) that you
had arthritis?’’ This deﬁnition is thought to provide credi-
ble overall arthritis surveillance with acceptable sensitivity
and speciﬁcity [32, 33] and has been used in other popu-
lation surveys [1, 31].
HRQOL instruments
The six HRQOL indexes are described in Fryback et al.
[23]. Brieﬂy, the EQ-5D, which we computed using US
weights [34], is a ﬁve-question index asking about mobil-
ity, self-care, restrictions of usual activities, pain/discom-
fort and anxiety/depression. The SF-6D [27] is constructed
using 11 of 36 questions from the widely used SF-36v2
TM
[35]. The SF-6D uses questions concerning physical
function, limitations in role functioning, social function,
pain, mental health, and vitality. The HUI2 [25] and HUI3
[26] are related measures computed from the Health Util-
ities Index questionnaire. The HUI2 deﬁnes health status
on six domains (sensation, mobility, emotion, cognition,
self-care, and pain—we excluded an optional fertility
dimension). HUI3 addresses vision, hearing, speech,
ambulation, dexterity, emotion, cognition, and pain. The
QWB-SA summarizes functioning and mobility, physical
activity, and social activity, but also collects extensive
information about 58 symptoms/problem complexes. The
four domains into a single score QWB-SA [28]. Finally,
the HALex [29] is an index-constructed post hoc to use
data collected by the recurring NHIS. HALex combines
level of physical activity restriction with self-rated health
(excellent, very good, good, fair, poor) and derives single
weighted score using preferences from the HUI.
Three indexes, EQ-5D, HUI2, and HUI3 allow scores
less than 0.0 to reﬂect health states considered worse than
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indexes’ weighting schemes were derived.
Statistical analysis
To allow analyses to reﬂect the target US population,
observations in the NHMS data set are supplied with sur-
vey weights computed ﬁrst as the inverse sampling prob-
ability for each participant based on the sampling scheme
and then post-stratiﬁed to the US Census 2000 population
by age, gender, and race [23]. Descriptive statistics
(Table 1) and mean estimates of the six HRQOL indexes
(Table 2, Fig. 1,‘ ‘ Appendix’’) incorporated these weights
using the ‘‘svyset’’ collection of commands available in
STATA10.2 (Stata Corp., College Station, TX).
Unadjusted estimates of the six HRQOL indexes, strat-
iﬁed by age, gender, and arthritis category, were computed
as the survey-weighted mean and standard error (SE) of the
index for each age/gender/arthritis combination (Table 2).
Age-groups were deﬁned as 35–44, 45–54, 55–64, 65–74,
and 75–89. Estimates stratiﬁed by age-group and arthritis
category were then recomputed adjusting for demographic
variables and comorbidities selected based on Table 1 (see
Fig. 1,‘ ‘ Appendix’’). Under this approach, the HRQOL
index is modeled as a continuous variable using survey-
weighted linear regression. Predictors in the model consist
of dummy variables for age-group and arthritis category,
the interaction of age-group and arthritis category, and the
following: gender, race (White, African American, Other),
level of education (less than high school, high school, some
post-high school, 4-year college degree or higher), house-
hold income (\$20,000, $20,000–$34,999, $35,000–
$74,999, [$75,000), body mass index (BMI) as a contin-
uous variable, and the presence or absence of the following
self-reported health care professional-diagnosed comor-
bidities: coronary heart disease, diabetes, stroke, COPD,
and sleeping disorder. We did not adjust for depression as
mental health is represented in each of 6 HRQOL indexes.
The following covariates were centered to the US Census
2000 population proportions where possible and to survey
means and proportions from NHMS when census data were
not available (centering values provided in parentheses):
male gender (0.474), BMI (27.6), history of coronary heart
disease (0.092), history of stroke (0.039), diabetes (0.122),
COPD (0.131), and sleeping disorder (0.080). For k-level
categorical variables, k-1 indicator variables each centered
to the population or survey proportion for the appropri-
ate level were incorporated into the model as follows:
race (African American: 0.105, other race: 0.086), educa-
tion (high school: 0.286, some post-high school: 0.273,
4-year college degree or higher: 0.244), and income
level ($20,000–$34,999: 0.183, $35,000–$74,999: 0.353,
$75,000?: 0.249). Estimates of HRQOL mean and SE of
the mean for each age-group/arthritis category were found
by applying the appropriate post-estimation linear contrast
involving the intercept term, dummy variables for age-
group and arthritis category, and age-group-by-arthritis
interaction terms.
Results
Brieﬂy, NHMS showed 3,844 adults aged 35–89 were
reached by random digit telephone sampling, representing
an estimated response rate of 56% between June 2005 and
August 2006. The unweighted sample constituted of 57.3%
women, 44% aged 65–89, and 28% African American
(Table 1)[ 23]. The rough estimate for response rates
(based on comparing the age distribution weighted by
inverse sampling probability with that weighted by post-
stratiﬁcation weights) was as follows: 39% for age
35–44 years, 67% for age 45–54 years, 69% for age
55–64 years, 55% for age 65–74 years, and 59% for age
75–89 years. The six indexes generally showed similar
patterns of decrease with mean scores.
In the present analysis, the estimated population preva-
lence of self-reported arthritis in the 35–89 age range of
non-institutionalized individuals was 31%, or 44.2 million
adults among the 141.2 million US adults represented by
NHMS in the Census 2000 population. Similar prevalence
estimates were found in other large national surveys in the
United States (Table 3). People with arthritis were more
likely to be women, older, of lower socioeconomic status,
and had more self-reported comorbidities (Table 1) than
were those not reporting arthritis.
Adults with arthritis had lower mean HRQOL than adults
without arthritis in all gender by age-groups for each of the
six HRQOL indexes (Table 2). The EQ-5D means were
highest for each age stratum; HUI2, HUI3, SF-6D, and
HALexmeanswereinthemid-range;andQWB-SAwerethe
lowestforthearthritisandnon-arthritisgroups.Womenwith
arthritis had lower mean HRQOL indexes in the 55–89 age-
groups (except for HUI2 where women and men had the
same mean score of 0.68 for the 55–64 age-group). Women
and men without arthritis had similar mean HRQOL scores
for all 6 indexes when stratiﬁed by age-groups.
Results of the adjusted analyses are shown graphically in
the Fig. 1 (and ‘‘Appendix’’). Each subpanel corresponds to
anHRQOLindexandtheestimatedHRQOLmeanacrossthe
age-groups is presented separately for patients with and
without arthritis. Error bars correspond to 95% conﬁdence
intervals based on the standard errors estimated from the
models. Tests of the set of age-group-by-arthritis interaction
terms were non-signiﬁcant and suggest that the arthritis
effect remains constant across the age-groups. Similar to
unadjusted models (Table 2), for individuals reporting
Qual Life Res (2011) 20:1131–1140 1133
123Table 1 Characteristics of adults with and without self-reported arthritis
Arthritis No arthritis Total P-value
N Weighted (%) N Weighted (%)
Sex
Male 555 43.4 1,083 48.8 1,638 0.0579
Female 1,002 56.6 1,199 51.2 2,201
Total 1,557 2,282 3,839
Age category
35–44 107 15.5 535 39.0 642 \.0001
45–54 226 18.3 600 26.3 826
55–64 297 25.3 387 17.5 684
65–74 507 22.1 457 10.5 964
75–89 420 18.7 303 6.7 723
Total 1,557 2,282 3,839
Race category
White 1,038 84.3 1,520 80.6 2,558 0.0924
Black 458 10.1 628 10.8 1,086
Other races 58 5.7 119 8.5 177
Total 1,554 2,267 3,821
Income category
\$20,000 436 17.5 345 8.2 781 \.0001
$20,000–$34,999 308 20.1 390 13.5 698
$35,000–$74,999 437 35.6 737 36.6 1,174
$75,000
? 225 26.8 636 41.8 861
Total 1,406 2,108 3,514
Education
\High school 264 11.6 200 6.8 464 \.0001
High school 513 30.6 643 27.2 1,156
Some post-high school 345 25.4 510 20.7 855
4-year college degree or higher 426 32.3 915 45.3 1,341
Total 1,548 2,268 3,816
Body mass index category
\18.5 14 0.8 29 1.7 43 \.0001
18.5–25 307 22.9 650 34.8 957
25–30 485 38.2 784 36.5 1,269
[30 598 38.2 570 27.0 1,168
Total 1,404 2,033 3,437
Coronary heart disease
Yes 294 16.3 189 6.0 483 \.0001
No 1,253 83.8 2,092 94.0 3,345
Total 1,547 2,281 3,828
Stroke
Yes 135 7.7 87 2.1 222 \.0001
No 1,419 92.3 2,195 97.9 3,614
Total 1,554 2,282 3,836
Diabetes mellitus
Yes 413 17.7 313 9.8 726 \.0,001
No 1,143 82.3 1,968 90.2 3,111
Total 1,556 2,281 3,837
Sleep disorder
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123arthritis, the HRQOL scores were highest for EQ-5D and
lowest for QWB-SA for all age-groups. In general, the
HRQOLscoresdeclinedfrom35-to64-yearage-groupsand
then showed a ‘‘bump up’’ in the 65–74-year age-group for
both arthritis and non-arthritis groups.
Discussion
Using a large nationally representative population-based
survey, we show that adults with self-reported arthritis have
lowerHRQOLscoresthanadultswhodidnotreportarthritis
after adjusting for age and sex and even after adjusting for
several covariates. This was seen across the six HRQOL
instruments. In addition, our study provides important
national age-related reference averages for six HRQOL
indexesforadultswithself-reportedarthritisthatcanbeused
in future decision and cost-effectiveness analyses.
Arthritis is very common in age groups 35–89 years and a
major contributor to HRQOL in the US population. The
prevalence ofarthritishas been steadily increasing [1,36]. We
founda31%prevalenceofself-reportedarthritisbytheNHMS
study. Previous surveys that differ in age-groups targeted and
how arthritis was deﬁned have shown similar prevalence. In
the Medical Expenditures Panel Survey Household Compo-
nent (MEPS-HC; computer-assisted personal interviewing),
theprevalenceofarthritisin35–89age-groupwas30%in2003
[37]( T a b l e3). In two other national representative surveys,
the US ValuationoftheEuroQol EQ-5D Health StatesSurvey
in 2002 (USVEQ; self-administered with interviewer present)
[24] and Joint Canada/United States Survey of Health from
2002 to 2003(JCUSH; telephone survey) [38], the prevalence
of self-reported arthritis for ages 35–89 was consistently esti-
mated at around 30% (Table 3).
One of our interesting results is the declining HRQOL
scores in the 35–64 age-group seen in both arthritis and
non-arthritis groups and then a trend toward an improve-
ment in their HRQOL in the 65–74-year age-group. This
interesting ﬁnding was also reported for the whole cohort
in the original publication from the NHMS [23]. Fryback
et al. suggest that this may relate to reporting bias of poor
HRQOL in 55–64 age-group (baby boomers) or greater
HRQOL in 65–74 age-group (recent retirees). Another
potential reason may be selective non-participation in the
survey by age and health around retirement age. Perhaps,
more healthy people in the 55–64 age-group may be too
busy, or perhaps, less healthy people in the 65–74 group
may be too ill to participate.
Our data have important implications for public policy.
First,ouranalysisprovidesage-relatedHRQOLscoresforsix
commonly used measures that can be used in future decision
and cost-effectiveness analyses. The US Public Health Ser-
vicePanelonCost-EffectivenessinHealthandMedicine[39]
recommended using HRQOL scores based on preference
weights derived from the general public, rather than from
patients, for cost-effectiveness analyses. The indexes used
here meet this requirement. We provide population-based
estimates of HRQOL burden for each age-group-by-arthritis
stratum. Second, previous studies have found that the mini-
mally important difference in HRQOL preference-based
scores—the smallest difference in scores that patients per-
ceiveasbeneﬁcial[40]—isabout0.03,witharangefrom0.01
to 0.10 [41–43]. The differences in HRQOL scores between
arthritis and non-arthritis groups in our study exceed the
minimally important difference and are thus clinically
meaningful. Third, as previously reported, each of the six
HRQOL measures provides different scores associated with
the impact of arthritis, thus choice of measure can affect
estimatesofquality-adjustedlifeyears(QALYs)gainedbyan
intervention andthusdifferentincrementalcost-effectiveness
estimates. In an analysis of treatment of rheumatoid arthritis
with combination of inﬂiximab and methotrexate versus
Table 1 continued
Arthritis No arthritis Total P-value
N Weighted (%) N Weighted (%)
Yes 235 15.2 121 4.7 356 \.0001
No 1,320 84.8 2,158 95.3 3,478
Total 1,555 2,279 3,834
Respiratory problems
Yes 376 21.6 268 9.3 644 \.0001
No 1,180 78.4 2,014 90.7 3,194
Total 1,556 2,282 3,838
Depression
Yes 303 20.9 256 12.1 559 0.0001
No 1,252 79.1 2,025 87.9 3,277
Total 1,555 2,281 3,836
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HRQOL measures (EQ-5D, HUI2, HUI3, and SF-6D) pro-
vided different QALYs and therefore different incremental
cost-effectivenessscores.Intheiranalysis,HUI3producedthe
largest incremental QALYs gain followed by EQ-5D, HUI2,
and SF-6D. It may be necessary for analysts doing cost-
effectiveness analyses to agree upon a common measure of
HRQOL in order to standardize analytic results.
Our survey is not without limitations. NHMS was
administered using a random digital dial telephone survey,
which may have had somewhat higher response rates among
people whoare moreeducated and/or with higher household
incomescomparedwithUSCensusﬁguresfortheyear2000.
Thus, the NHMS may have reached somewhat more healthy
persons [23]. Although the question eliciting arthritis diag-
nosishasbeenwidelyusedinsimilarsurveys,caseswerenot
veriﬁed by examination or medical records. People
respondingtotelephonesurveystendtoreportslightlybetter
healththanthoserespondingtoself-administered,paper,and
pencil questionnaires [45]. Telephone-based health surveys
Table 2 Unadjusted mean (SE) HRQOL index score of US adults aged 35–89 by gender, age, and arthritis
Index Whole group Men Women
Arthritis No arthritis Arthritis No arthritis Arthritis No arthritis
EQ-5D
35–44 0.77 (0.03) 0.91 (0.01) 0.78 (0.06) 0.92 (0.01) 0.77 (0.03) 0.91 (0.01)
45–54 0.78 (0.02) 0.91 (0.01) 0.78 (0.02) 0.91 (0.01) 0.78 (0.03) 0.90 (0.01)
55–64 0.77 (0.01) 0.90 (0.01) 0.78 (0.02) 0.90 (0.01) 0.76 (0.02) 0.90 (0.01)
65–74 0.80 (0.01) 0.91 (0.01) 0.82 (0.02) 0.90 (0.01) 0.79 (0.01) 0.91 (0.01)
75–89 0.80 (0.01) 0.89 (0.01) 0.82 (0.01) 0.89 (0.01) 0.77 (0.01) 0.89 (0.01)
HALex
35–44 0.75 (0.03) 0.86 (0.01) 0.74 (0.04) 0.87 (0.01) 0.75 (0.04) 0.86 (0.01)
45–54 0.71 (0.03) 0.85 (0.01) 0.74 (0.03) 0.83 (0.01) 0.69 (0.04) 0.86 (0.01)
55–64 0.68 (0.03) 0.81 (0.02) 0.68 (0.03) 0.81 (0.02) 0.68 (0.04) 0.81 (0.03)
65–74 0.68 (0.02) 0.82 (0.01) 0.70 (0.02) 0.82 (0.02) 0.67 (0.02) 0.81 (0.02)
75–89 0.68 (0.02) 0.80 (0.01) 0.71 (0.03) 0.80 (0.02) 0.64 (0.03) 0.81 (0.02)
HUI2
35–44 0.74 (0.03) 0.88 (0.01) 0.72 (0.06) 0.91 (0.01) 0.75 (0.03) 0.87 (0.01)
45–54 0.77 (0.02) 0.88 (0.01) 0.75 (0.04) 0.89 (0.01) 0.78 (0.03) 0.87 (0.01)
55–64 0.76 (0.02) 0.87 (0.01) 0.78 (0.03) 0.86 (0.01) 0.74 (0.03) 0.87 (0.01)
65–74 0.79 (0.01) 0.89 (0.01) 0.81 (0.02) 0.89 (0.01) 0.79 (0.02) 0.89 (0.02)
75–89 0.78 (0.01) 0.88 (0.01) 0.80 (0.01) 0.88 (0.02) 0.77 (0.02) 0.88 (0.01)
HUI3
35–44 0.64 (0.05) 0.85 (0.01) 0.62 (0.09) 0.89 (0.02) 0.64 (0.06) 0.84 (0.02)
45–54 0.71 (0.03) 0.86 (0.01) 0.7 (0.05) 0.87 (0.01) 0.72 (0.04) 0.86 (0.01)
55–64 0.68 (0.03) 0.84 (0.01) 0.71 (0.04) 0.82 (0.02) 0.67 (0.05) 0.86 (0.02)
65–74 0.73 (0.02) 0.86 (0.02) 0.75 (0.03) 0.85 (0.02) 0.72 (0.03) 0.87 (0.02)
75–89 0.69 (0.02) 0.83 (0.02) 0.71 (0.03) 0.83 (0.03) 0.67 (0.03) 0.84 (0.02)
QWB-SA
35–44 0.59 (0.03) 0.71 (0.01) 0.60 (0.04) 0.74 (0.01) 0.58 (0.03) 0.69 (0.01)
45–54 0.59 (0.02) 0.7 (0.01) 0.58 (0.02) 0.71 (0.01) 0.59 (0.02) 0.68 (0.01)
55–64 0.58 (0.02) 0.68 (0.01) 0.62 (0.02) 0.69 (0.01) 0.55 (0.02) 0.67 (0.01)
65–74 0.59 (0.01) 0.68 (0.01) 0.06 (0.01) 0.67 (0.01) 0.58 (0.01) 0.69 (0.02)
75–89 0.56 (0.01) 0.66 (0.01) 0.57 (0.02) 0.64 (0.02) 0.55 (0.01) 0.69 (0.02)
SF-6D
35–44 0.74 (0.02) 0.81 (0.01) 0.74 (0.04) 0.82 (0.01) 0.74 (0.03) 0.81 (0.01)
45–54 0.74 (0.02) 0.82 (0.01) 0.76 (0.02) 0.82 (0.01) 0.73 (0.02) 0.81 (0.01)
55–64 0.72 (0.01) 0.82 (0.01) 0.73 (0.02) 0.82 (0.01) 0.71 (0.02) 0.81 (0.01)
65–74 0.73 (0.01) 0.83 (0.01) 0.75 (0.01) 0.83 (0.01) 0.72 (0.01) 0.82 (0.02)
75–89 0.71 (0.01) 0.82 (0.01) 0.73 (0.01) 0.81 (0.01) 0.69 (0.01) 0.82 (0.02)
1136 Qual Life Res (2011) 20:1131–1140
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Fig. 1 Means (SE) estimating non-institutionalized US population
health-related quality-of-life (HRQOL) by age are shown for self-
reported arthritis and no arthritis using 6 standardized indexes. The
mean estimates are adjusted for gender, race, level of education,
annual household income body mass index, and the presence or
absence of the following self-reported health care professional-
diagnosed comorbidities: coronary heart disease, diabetes, stroke,
COPD, and sleeping disorder
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123were apparently little affected by cell phone usage in the
timeframe of the NHMS [46].
In conclusion, this study provides important national
reference averages for six HRQOL indexes for adults with
self-reported arthritis for future decision analysis and cost-
effectiveness analysis.
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Appendix
See Table 4.
Table 3 Arthritis in four nationally representative data sets for ages 35–89
Arthritis No arthritis Arthritis question asked
Unweighted Weighted Unweighted Weighted
N % N %
NHMS 1,557 31.3 2,282 68.7 Have you ever been told (by a doctor or other health professional) that
you had arthritis?
MEPS* (proxy
included)
4,253 30.0 9,728 70.0 (Have/Has) (PERSON) ever been told by a doctor or other health
professional that (PERSON) had arthritis?
(non-proxy only) 4,225 29.9 9,699 70.1
USVEQ 693 30.1 1,704 69.9 Please read this card and tell me if you have ever been told by a health
professional that you have any of the following conditions: Arthritis
JCUSH (proxy
included)
1,104 25.2 2,804 74.8 Have you ever been told by a doctor or other health professional that
you have arthritis, not including ﬁbromyalgia?
(non-proxy only)
[US respondents
only]
1,065 25.1 2,728 74.9
NHMS National Health Measurement Study, MEPS Medical Expenditures Panel Survey, USVEQ US Valuation of the EuroQol EQ-5D Health
States Survey, JCUSH Joint Canada/United States Survey of Health
* All estimates were generated within the 35–89 age-group using study-speciﬁc survey weights except for MEPS which surveys ages 18–90 top
coding all ages[85 as ‘‘85’’ for conﬁdentiality purposes. So the MEPS survey-weighted estimates represent ages 35–90
Table 4 Mean (SE) HRQOL index score of US adults aged 35–89 by
gender, age, and arthritis
Index Arthritis No arthritis
EQ-5D
35–44 0.77 (0.02) 0.88 (0.01)
Table 4 continued
Index Arthritis No arthritis
45–54 0.78 (0.01) 0.87 (0.01)
55–64 0.78 (0.01) 0.86 (0.01)
65–74 0.83 (0.01) 0.90 (0.01)
75–89 0.82 (0.01) 0.88 (0.01)
HALex
35–44 0.74 (0.02) 0.81 (0.01)
45–54 0.71 (0.02) 0.78 (0.01)
55–64 0.69 (0.03) 0.77 (0.02)
65–74 0.75 (0.01) 0.82 (0.01)
75–89 0.74 (0.02) 0.80 (0.01)
HUI2
35–44 0.74 (0.03) 0.85 (0.01)
45–54 0.77 (0.02) 0.84 (0.01)
55–64 0.76 (0.02) 0.84 (0.01)
65–74 0.83 (0.01) 0.88 (0.01)
75–89 0.83 (0.01) 0.88 (0.01)
HUI3
35–44 0.63 (0.04) 0.8 (0.01)
45–54 0.7 (0.03) 0.8 (0.01)
55–64 0.69 (0.03) 0.79 (0.01)
65–74 0.79 (0.02) 0.84 (0.02)
75–89 0.76 (0.02) 0.83 (0.02)
QWB-SA
35–44 0.59 (0.02) 0.68 (0.01)
45–54 0.59 (0.01) 0.67 (0.01)
55–64 0.59 (0.01) 0.65 (0.01)
65–74 0.64 (0.01) 0.67 (0.01)
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